GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » Inventories, Raw Materials & Components

NAMS (NewAmsterdam Pharma Co NV) Inventories, Raw Materials & Components : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Inventories, Raw Materials & Components?

NewAmsterdam Pharma Co NV's inventories, raw materials & components for the quarter that ended in Dec. 2024 was $0.00 Mil.


NewAmsterdam Pharma Co NV Inventories, Raw Materials & Components Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV Inventories, Raw Materials & Components Chart

NewAmsterdam Pharma Co NV Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Raw Materials & Components
- - - - -

NewAmsterdam Pharma Co NV Quarterly Data
Dec20 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NewAmsterdam Pharma Co NV Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


NewAmsterdam Pharma Co NV Business Description

Industry
Traded in Other Exchanges
Address
Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.